MINNEAPOLIS, March 24, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells. UltiMatrix RGF BME addresses the market need for a dependable, high concentration cell scaffolding matrix with compositional and physical properties specifically designed for use in generating advanced 2D and 3D cell culture models. Cultrex UltiMatrix RGF BME matrix improvements include increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength while reducing the dependency on supplemental growth factors.

“Cultrex UltiMatrix BME offers improvements to matrix hydrogels that are urgently needed to support the increased use of organoids and pluripotent stem cells for drug discovery research, personalized medicine, and regenerative medicine. We’re very excited to add this advanced matrix to our portfolio,” said Dave Eansor, President, Protein Sciences Segment.

The full line of Cultrex BME can be found on the R&D Systems Website: Cultrex BME

Bio-Techne continues to support organoid and stem cell research by manufacturing reagents critical for cell culture, including recombinant proteins, small molecules, extracellular matrices, media and media supplements.

Click the link to learn more about Bio-Techne Corporation (NASDAQ: TECH)

This content was supplied by Bio-Techne Corporation.

Bio-Techne Corporation (MN, USA) recently announced the launch of their new product, Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel designed to significantly improve performance and consistency for culturing organoids and pluripotent stem cells.

The continued advancement of the field of regenerative medicine calls for more refined technologies to generate advanced 2D and 3D culture models. To this end, Bio-Techne have sought to develop a dependable, high concentration cell scaffolding matrix with compositional and physical properties specifically designed to address this need. The matrix improvements incorporated in this product include increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength while reducing the dependency on supplemental growth factors.

“Cultrex UltiMatrix [RGF] BME offers improvements to matrix hydrogels that are urgently needed to support the increased use of organoids and pluripotent stem cells for drug discovery research, personalized medicine, and regenerative medicine,” commented Dave Eansor, President of the Protein Sciences Segment at Bio-Techne. “We’re very excited to add this advanced matrix to our portfolio.”

Bio-Techne continues to support support organoid and stem cell research through the manufacture of reagents critical for cell culture, as part of its commitment to the wider life sciences industry.